Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$128.77 USD
+1.38 (1.08%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $128.69 -0.08 (-0.06%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SRPT 128.77 +1.38(1.08%)
Will SRPT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for SRPT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SRPT
Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?
What's in Store for Puma Biotechnology (PBYI) in Q1 Earnings?
SRPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Fusion (FUSN) to Report Q1 Earnings: Here's What to Expect
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Other News for SRPT
Optimistic Outperform Rating on Sarepta Therapeutics Amid Strong Elevidys Demand and Potential Label Expansion
Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
Edgewise gets EU orphan drug status for muscular dystrophy drug
Analysts Offer Insights on Healthcare Companies: Elevance Health (ELV), Sarepta Therapeutics (SRPT) and Intuitive Surgical (ISRG)
As more rare disease therapies launch, their prices are rising